The rising popularity of weight-loss drugs, particularly GLP-1 receptor agonists like Ozempic and Wegovy, is prompting a significant conversation about potential shifts in food demand, not just in the United States, but increasingly across Europe. While initial uptake was concentrated in North America, these medications are gaining traction in European markets, raising questions about their long-term impact on the food and beverage industry. The core of the issue revolves around a simple premise: if a significant portion of the population experiences reduced appetite and altered food preferences, what happens to the demand for various food products? Understanding the impact of GLP-1s on European food demand requires a nuanced gaze at adoption rates, usage patterns, and the evolving consumer landscape.
The global market for GLP-1s was estimated at roughly $70 billion in 2025, encompassing both diabetes treatment and weight management, according to industry analysis. While approximately 12% of US adults are currently using these drugs, estimates suggest that at least 2% of adults in Europe and the UK – roughly nine to ten million people – are similarly utilizing them. This figure, compiled from public health data, consumer surveys, and revenue reports from manufacturers like Novo Nordisk and Eli Lilly, is likely conservative, as real-world usage often outpaces official data collection. The potential for disruption is real, and food companies are beginning to assess the implications.
Uneven Adoption Across Europe
The rollout of GLP-1s hasn’t been uniform across the continent. Wealthier nations, such as the United Kingdom, Germany, and the Nordic countries, have seen faster adoption rates compared to Central and Eastern European countries. This disparity isn’t necessarily due to lower rates of obesity in the latter – in fact, some Central and Eastern European nations have among the highest obesity rates in Europe – but rather reflects differences in healthcare access, affordability, and awareness. The cost of these medications remains a significant barrier for many, even in countries with universal healthcare systems. A recent KFF poll highlighted that half of those using GLP-1s in the US find the drugs difficult to afford, a concern likely mirrored in Europe.
The user base is also diverse. Individuals are accessing these drugs through various pathways: prescriptions for Type 2 diabetes, private out-of-pocket purchases for weight management, and, in some cases, through off-label prescriptions. Demographic data indicates that older consumers and women are currently overrepresented among GLP-1 users, according to the KFF poll. This suggests that marketing and awareness campaigns may be more effectively reaching these groups, or that these demographics are more likely to seek medical intervention for weight-related health concerns.
The Challenge of Adherence and its Impact on Food Trends
A crucial factor influencing the long-term impact on food demand is medication adherence. Studies indicate that approximately 50% of individuals discontinue GLP-1s within one year, as reported in a study published in the BMJ. Reasons for discontinuation range from cost and side effects to simply reaching a desired weight. This fluctuating usage pattern presents a complex scenario for food and beverage companies. Demand for certain products might experience temporary surges and declines as consumers cycle on and off the medication, creating volatility in the market.
The specific effects on food demand are still unfolding, but early observations suggest a shift away from highly processed foods, sugary drinks, and calorie-dense snacks. Users often report a diminished craving for these items, and a greater preference for protein-rich foods and smaller portion sizes. This isn’t a blanket rejection of all indulgent foods, but rather a recalibration of appetite and taste preferences. Companies specializing in healthier options may see increased demand, while those heavily reliant on products traditionally associated with overconsumption could face challenges. The impact isn’t limited to specific food categories. it extends to restaurant choices, meal planning, and overall dietary habits.
Beyond Weight Loss: The Broader Health Implications
The implications of widespread GLP-1 use extend beyond the food industry. These medications have demonstrated positive effects on cardiovascular health, reducing the risk of heart attack and stroke in some patients. This could lead to reduced healthcare costs in the long run, but also raises questions about the sustainability of healthcare systems as demand for these expensive drugs increases. The potential for nutrient deficiencies due to reduced food intake is a concern that requires ongoing monitoring and dietary guidance for patients.
Looking Ahead: Monitoring and Adaptation
The long-term effects of GLP-1s on European food demand remain to be seen. Continued monitoring of adoption rates, usage patterns, and consumer behavior will be crucial for both the pharmaceutical industry and the food and beverage sector. Food companies will demand to adapt their product portfolios and marketing strategies to cater to evolving consumer preferences. This may involve developing healthier alternatives, reducing portion sizes, and focusing on products that align with the dietary needs of individuals using these medications. The European Food Safety Authority (EFSA) and national food safety agencies will likely play a key role in providing guidance and ensuring that food products meet evolving nutritional standards.
The next key data point to watch will be the release of comprehensive sales figures for GLP-1s in Europe for the full year 2026, expected in early 2027. These figures will provide a clearer picture of the medication’s market penetration and its impact on consumer spending habits. As more data becomes available, a more accurate assessment of the transformative – or perhaps overhyped – potential of these drugs on the European food landscape will emerge.
What we have is a developing story, and we encourage readers to share their perspectives and experiences in the comments below.
Worth a look
